Associação de timomodulina na terapia de gatos com esporotricose cutânea disseminada: um estudo prospectivo
| Autor: | Gustavo Soares Forlani, Risciela Salardi Alves de Brito, Jéssica Paola Salame, Angelita Reis Gomes, Fábio Raphael Pascoti Bruhn, Isabel Martins Madrid, Márcia de Oliveira Nobre |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
040301 veterinary sciences Itraconazole Agriculture (General) Disease complexo Sporothrixschenkii Gastroenterology S1-972 0403 veterinary science 03 medical and health sciences Sporothrixschenkii complex Internal medicine medicine feline Prospective cohort study Survival rate 0303 health sciences CATS General Veterinary Sporotrichosis 030306 microbiology business.industry immunomodulators Zoonosis Agriculture 04 agricultural and veterinary sciences estudo clínico imunomoduladores terapia clinical study zoonosis medicine.disease antifungal therapy Disseminated cutaneous sporotrichosis Animal Science and Zoology business Agronomy and Crop Science medicine.drug |
| Zdroj: | Ciência Rural, Volume: 51, Issue: 6, Article number: e20200311, Published: 26 MAR 2021 Ciência Rural v.51 n.6 2021 Ciência Rural Universidade Federal de Santa Maria (UFSM) instacron:UFSM Ciência Rural, Vol 51, Iss 6 (2021) |
| Popis: | Feline sporotrichosis is a relevant mycose in veterinary medicine due to its severity and zoonotic potential and the fact that it can be difficult to treat. The immune status of the animal exerts influence on the prognosis of the disease and determines its clinical outcome. This study evaluated the efficacy of the immunomodulatory thymomodulin as an adjunct to antifungal therapy in cats with disseminated sporotrichosis; thymomodulin was used in association with itraconazole (ITL) and potassium iodide (KI) to treat this fungal disease in the feline patient. Thirty-one cats (n=31) diagnosed with disseminated cutaneous sporotrichosis were divided into two groups as follows: Group 1 (G1) (n=16), which included those animals that were treated with thymomodulin in association with ITL and KI, and Group 2 (G2) (n=15) which had pacientsthat received ITL and KI only. The response to different treatment modalities was assessed, considering the survival rate, time frame for the lesions to respond to therapy, and clinical improvement or deterioration according to a body condition score system. Animals from G1 had a survival rate of nearly 100% (93.6%) that was approximately twice higher than the survival rate of those animals from G2 (53%). Moreover, patients from G1 had a significantly better prognosis, improved body condition, and shorter time for remission of the extra cutaneous clinical signs (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|